<DOC>
	<DOCNO>NCT00165178</DOCNO>
	<brief_summary>The purpose study reduce side-effects anti-leukemia therapy . The therapy study base upon treatment information learn prior clinical research program well laboratory research .</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia Children</brief_title>
	<detailed_description>- Children acute lymphoblastic leukemia treat somewhat differently depend relative risk leukemia recur . Patients separate `` Standard Risk '' `` High Risk '' . - The treatment program group separate 4 phase . The phase treatment induction , central nervous system ( CNS ) therapy , intensification continuation . - The induction phase therapy last one month purpose kill detectable leukemia cell . Patients group receive follow medication : prednisone , vincristine , doxorubicin , methotrexate , leucovorin , asparaginase , cytarabine ( ARA-C ) , hydrocortisone . Patients `` Hight Risk '' group also receive dexrazoxane . - Patients whose leukemia find specific genetic abnormality involve gene chromosome 11 ( know MLL gene ) MLL intensification phase begin complete remission last 1 month . The drug involve MLL intensification : vincristine , methotrexate , leucovorin , hydrocortisone , cytarabine L-asparaginase . - CNS therapy begin immediately end induction therapy , remission document . This phase treatment last 3 week include series spinal tap instillation anti-leukemia drug . Four spinal tap perform two-week period . Both group receive vincristine , 6-mercaptopurine methotrexate/cytarabine/hydrocortisone . Patients `` High Risk '' group also receive doxorubicin dexrazoxane . - Radiation therapy also deliver patient `` High Risk '' group CNS therapy phase . Radiation give 8 daily treatment . The total dose radiation use study lower use past help reduce side effect without increase risk relapse . - The intensification phase begin CNS therapy end last 30 week . This phase intend reduce number leukemia cell body consist cycle chemotherapy repeat every three week weekly shot asparaginase . The drug administer group phase : prednisone dexamethasone , vincristine,6-mercaptopurine , methotrexate , E. coli asparaginase cytarabine . Patients `` High Risk '' group also receive doxorubicin dexrazoxane . - The continuation phase begin completion intensification phase goal eradicate leukemia body . It consist cycle chemotherapy repeat every 3 week continue patient remission 2 year . The drug administer phase vincristine , prednisone dexamethasone , 6-mercaptopurine , methotrexate cytarabine . - During trial two randomization , `` standard '' treatment `` investigational '' treatment . One randomization involve drug E. coli L-asparaginase two way dose drug . One way give standard dose drug administer year . The way start low dose measure amount drug blood every 3 week adjust dose necessary . The goal maintain adequate drug level low dos hope may reduce side effect drug . - The second randomization involve drug prednisone dexamethasone . Both drug use past help treat ALL know difference two drug , especially term side effect . Patients randomize either receive dexamethasone prednisone . - Throughout study blood test , urine test , spinal tap , bone marrow test perform monitor disease status , side effect medication complication therapy . - Quality life questionnaire also perform patient ( old 8 ) , parent patient 's clinician .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Acute lymphoblastic leukemia exclude know mature Bcell ALL presence follow : surface immunoglobulin , L3 morphology , ( 8 ; 14 ) ( q24 ; q32 ) , ( 8 ; 22 ) ( 2 ; 8 ) Age &gt; 12 month le 18 year Prior therapy except , 1 week steroid , emergent radiation therapy mediastinum Known HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Acute lymphoblastic leukemia child</keyword>
	<keyword>High Risk ALL</keyword>
	<keyword>Standard Risk ALL</keyword>
	<keyword>E. coli asparaginase</keyword>
</DOC>